VBL Therapeutics, a late-stage biopharmaceutical company based in Tel Aviv, Israel, has announced plans to establish a new facility for manufacturing biological drugs in Modiin, Israel as the company plans ahead for potential commercialization of VB-111, an intravenously administered anti-angiogenic agent and VBL’s lead product candidate being developed for treating solid tumors.

The site design enables modular expansion of manufacturing capacity while requiring limited capital resources in the immediate stage. The new facility will also include the company’s headquarters, discovery, research, and clinical development. VBL intends to operate and relocate to the new site in the second half of 2017.

Source: VBL Therapeutics